Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

MicroRNA and Oxidative Stress Interplay in the Context of Breast Cancer Pathogenesis.

Cosentino G, Plantamura I, Cataldo A, Iorio MV.

Int J Mol Sci. 2019 Oct 17;20(20). pii: E5143. doi: 10.3390/ijms20205143. Review.

2.

Decoding Immune Heterogeneity of Triple Negative Breast Cancer and Its Association with Systemic Inflammation.

Romero-Cordoba S, Meneghini E, Sant M, Iorio MV, Sfondrini L, Paolini B, Agresti R, Tagliabue E, Bianchi F.

Cancers (Basel). 2019 Jun 28;11(7). pii: E911. doi: 10.3390/cancers11070911.

3.

Editorial: From "Junk DNA" to Clinically Relevant Tools for Cancer Diagnosis, Staging, and Tailored Therapies: The Incredible Case of Non-Coding RNAs.

Iorio MV, Palmieri D.

Front Oncol. 2019 May 14;9:389. doi: 10.3389/fonc.2019.00389. eCollection 2019. No abstract available.

4.

Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial.

Di Cosimo S, Appierto V, Pizzamiglio S, Tiberio P, Iorio MV, Hilbers F, de Azambuja E, de la Peña L, Izquierdo M, Huober J, Baselga J, Piccart M, de Braud FG, Apolone G, Verderio P, Daidone MG.

Clin Cancer Res. 2019 Jul 1;25(13):3887-3895. doi: 10.1158/1078-0432.CCR-18-2507. Epub 2019 Feb 27.

PMID:
30814109
5.

WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer.

Castagnoli L, Cancila V, Cordoba-Romero SL, Faraci S, Talarico G, Belmonte B, Iorio MV, Milani M, Volpari T, Chiodoni C, Hidalgo-Miranda A, Tagliabue E, Tripodo C, Sangaletti S, Di Nicola M, Pupa SM.

Oncogene. 2019 May;38(21):4047-4060. doi: 10.1038/s41388-019-0700-2. Epub 2019 Jan 31.

6.

Expression of long non-coding RNA ENSG00000226738 (LncKLHDC7B) is enriched in the immunomodulatory triple-negative breast cancer subtype and its alteration promotes cell migration, invasion, and resistance to cell death.

Beltrán-Anaya FO, Romero-Córdoba S, Rebollar-Vega R, Arrieta O, Bautista-Piña V, Dominguez-Reyes C, Villegas-Carlos F, Tenorio-Torres A, Alfaro-Riuz L, Jiménez-Morales S, Cedro-Tanda A, Ríos-Romero M, Reyes-Grajeda JP, Tagliabue E, Iorio MV, Hidalgo-Miranda A.

Mol Oncol. 2019 Apr;13(4):909-927. doi: 10.1002/1878-0261.12446. Epub 2019 Feb 9.

7.

Loss of function of miR-342-3p results in MCT1 over-expression and contributes to oncogenic metabolic reprogramming in triple negative breast cancer.

Romero-Cordoba SL, Rodriguez-Cuevas S, Bautista-Pina V, Maffuz-Aziz A, D'Ippolito E, Cosentino G, Baroni S, Iorio MV, Hidalgo-Miranda A.

Sci Rep. 2018 Aug 16;8(1):12252. doi: 10.1038/s41598-018-29708-9.

8.

MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab.

Cataldo A, Piovan C, Plantamura I, D'Ippolito E, Camelliti S, Casalini P, Giussani M, Déas O, Cairo S, Judde JG, Tagliabue E, Iorio MV.

Oncotarget. 2018 Jun 15;9(46):27920-27928. doi: 10.18632/oncotarget.24723. eCollection 2018 Jun 15.

9.

The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer.

Forte L, Turdo F, Ghirelli C, Aiello P, Casalini P, Iorio MV, D'Ippolito E, Gasparini P, Agresti R, Belmonte B, Sozzi G, Sfondrini L, Tagliabue E, Campiglio M, Bianchi F.

BMC Cancer. 2018 May 23;18(1):586. doi: 10.1186/s12885-018-4500-9.

10.

MicroRNA co-expression patterns unravel the relevance of extra cellular matrix and immunity in breast cancer.

Dugo M, Huang X, Iorio MV, Cataldo A, Tagliabue E, Daidone MG, Wu J, Orlandi R.

Breast. 2018 Jun;39:46-52. doi: 10.1016/j.breast.2018.03.008. Epub 2018 Mar 26.

PMID:
29597130
11.

MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review.

Iorio MV, Croce CM.

EMBO Mol Med. 2017 Jun;9(6):852. doi: 10.15252/emmm.201707779. No abstract available.

12.

Commentary on microRNA Fingerprint in Human Epithelial Ovarian Cancer.

Iorio MV, Croce CM.

Cancer Res. 2016 Nov 1;76(21):6143-6145. No abstract available.

13.

Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers.

Di Modica M, Regondi V, Sandri M, Iorio MV, Zanetti A, Tagliabue E, Casalini P, Triulzi T.

Cancer Lett. 2017 Jan 1;384:94-100. doi: 10.1016/j.canlet.2016.09.013. Epub 2016 Sep 28.

14.

Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts.

Baroni S, Romero-Cordoba S, Plantamura I, Dugo M, D'Ippolito E, Cataldo A, Cosentino G, Angeloni V, Rossini A, Daidone MG, Iorio MV.

Cell Death Dis. 2016 Jul 28;7(7):e2312. doi: 10.1038/cddis.2016.224.

15.

miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer.

D'Ippolito E, Plantamura I, Bongiovanni L, Casalini P, Baroni S, Piovan C, Orlandi R, Gualeni AV, Gloghini A, Rossini A, Cresta S, Tessari A, De Braud F, Di Leva G, Tripodo C, Iorio MV.

Cancer Res. 2016 Sep 15;76(18):5562-72. doi: 10.1158/0008-5472.CAN-16-0140. Epub 2016 Jul 11.

16.

miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response.

Cataldo A, Cheung DG, Balsari A, Tagliabue E, Coppola V, Iorio MV, Palmieri D, Croce CM.

Oncotarget. 2016 Jan 5;7(1):786-97. doi: 10.18632/oncotarget.6381.

17.

PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells.

Plantamura I, Casalini P, Dugnani E, Sasso M, D'Ippolito E, Tortoreto M, Cacciatore M, Guarnotta C, Ghirelli C, Barajon I, Bianchi F, Triulzi T, Agresti R, Balsari A, Campiglio M, Tripodo C, Iorio MV, Tagliabue E.

Mol Oncol. 2014 Jul;8(5):968-81. doi: 10.1016/j.molonc.2014.03.015. Epub 2014 Mar 27.

18.

Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.

Zappasodi R, Cavanè A, Iorio MV, Tortoreto M, Guarnotta C, Ruggiero G, Piovan C, Magni M, Zaffaroni N, Tagliabue E, Croce CM, Zunino F, Gianni AM, Di Nicola M.

Int J Cancer. 2014 Nov 1;135(9):2034-45. doi: 10.1002/ijc.28852. Epub 2014 Mar 26. Erratum in: Int J Cancer. 2017 Nov 1;141(9):E6.

19.

MicroRNAs and triple negative breast cancer.

D'Ippolito E, Iorio MV.

Int J Mol Sci. 2013 Nov 11;14(11):22202-20. doi: 10.3390/ijms141122202. Review.

20.

MicroRNA profiling in ovarian cancer.

Iorio MV, Croce CM.

Methods Mol Biol. 2013;1049:187-97. doi: 10.1007/978-1-62703-547-7_14.

PMID:
23913217
21.

Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status.

Di Leva G, Piovan C, Gasparini P, Ngankeu A, Taccioli C, Briskin D, Cheung DG, Bolon B, Anderlucci L, Alder H, Nuovo G, Li M, Iorio MV, Galasso M, Santhanam R, Marcucci G, Perrotti D, Powell KA, Bratasz A, Garofalo M, Nephew KP, Croce CM.

PLoS Genet. 2013;9(3):e1003311. doi: 10.1371/journal.pgen.1003311. Epub 2013 Mar 7. Erratum in: PLoS Genet. 2013 Apr;9(4). doi:10.1371/annotation/92dfa670-d431-4d68-b70b-706df1f93e46. Ramasamy, Santhanam [corrected to Santhanam, Ramasamy].

22.

Increased sensitivity to chemotherapy induced by CpG-ODN treatment is mediated by microRNA modulation.

De Cecco L, Berardi M, Sommariva M, Cataldo A, Canevari S, Mezzanzanica D, Iorio MV, Tagliabue E, Balsari A.

PLoS One. 2013;8(3):e58849. doi: 10.1371/journal.pone.0058849. Epub 2013 Mar 6.

23.

Causes and consequences of microRNA dysregulation.

Iorio MV, Croce CM.

Cancer J. 2012 May-Jun;18(3):215-22. doi: 10.1097/PPO.0b013e318250c001. Review.

24.

Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer.

Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, Nuovo G, Tortoreto M, Sasso M, Plantamura I, Triulzi T, Taccioli C, Tagliabue E, Iorio MV, Croce CM.

Mol Oncol. 2012 Aug;6(4):458-72. doi: 10.1016/j.molonc.2012.03.003. Epub 2012 Apr 19.

25.

microRNA involvement in human cancer.

Iorio MV, Croce CM.

Carcinogenesis. 2012 Jun;33(6):1126-33. doi: 10.1093/carcin/bgs140. Epub 2012 Apr 3. Review.

26.

MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review.

Iorio MV, Croce CM.

EMBO Mol Med. 2012 Mar;4(3):143-59. doi: 10.1002/emmm.201100209. Epub 2012 Feb 20. Review. Erratum in: EMBO Mol Med. 2017 Jun;9(6):852.

27.

Breast cancer and microRNAs: therapeutic impact.

Iorio MV, Casalini P, Piovan C, Braccioli L, Tagliabue E.

Breast. 2011 Oct;20 Suppl 3:S63-70. doi: 10.1016/S0960-9776(11)70297-1. Review.

28.

Interplay between microRNAs and the epigenetic machinery: an intricate network.

Iorio MV, Piovan C, Croce CM.

Biochim Biophys Acta. 2010 Oct-Dec;1799(10-12):694-701. doi: 10.1016/j.bbagrm.2010.05.005. Epub 2010 May 20. Review.

PMID:
20493980
29.

Reprogramming of miRNA networks in cancer and leukemia.

Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Abu Jarour R, Desponts C, Teitell M, Baffa R, Aqeilan R, Iorio MV, Taccioli C, Garzon R, Di Leva G, Fabbri M, Catozzi M, Previati M, Ambs S, Palumbo T, Garofalo M, Veronese A, Bottoni A, Gasparini P, Harris CC, Visone R, Pekarsky Y, de la Chapelle A, Bloomston M, Dillhoff M, Rassenti LZ, Kipps TJ, Huebner K, Pichiorri F, Lenze D, Cairo S, Buendia MA, Pineau P, Dejean A, Zanesi N, Rossi S, Calin GA, Liu CG, Palatini J, Negrini M, Vecchione A, Rosenberg A, Croce CM.

Genome Res. 2010 May;20(5):589-99. doi: 10.1101/gr.098046.109.

30.

MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer.

Di Leva G, Gasparini P, Piovan C, Ngankeu A, Garofalo M, Taccioli C, Iorio MV, Li M, Volinia S, Alder H, Nakamura T, Nuovo G, Liu Y, Nephew KP, Croce CM.

J Natl Cancer Inst. 2010 May 19;102(10):706-21. doi: 10.1093/jnci/djq102. Epub 2010 Apr 13.

31.

MicroRNAs and future therapeutic applications in cancer.

Casalini P, Iorio MV.

J BUON. 2009 Sep;14 Suppl 1:S17-22. Review.

32.

MicroRNAs in cancer: small molecules with a huge impact.

Iorio MV, Croce CM.

J Clin Oncol. 2009 Dec 1;27(34):5848-56. doi: 10.1200/JCO.2009.24.0317. Epub 2009 Nov 2. Review.

33.

microRNA-205 regulates HER3 in human breast cancer.

Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, Ménard S, Croce CM, Tagliabue E.

Cancer Res. 2009 Mar 15;69(6):2195-200. doi: 10.1158/0008-5472.CAN-08-2920. Epub 2009 Mar 10.

34.

MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer.

Iorio MV, Casalini P, Tagliabue E, Ménard S, Croce CM.

Eur J Cancer. 2008 Dec;44(18):2753-9. doi: 10.1016/j.ejca.2008.09.037. Epub 2008 Nov 18. Review.

PMID:
19022662
35.

UCbase & miRfunc: a database of ultraconserved sequences and microRNA function.

Taccioli C, Fabbri E, Visone R, Volinia S, Calin GA, Fong LY, Gambari R, Bottoni A, Acunzo M, Hagan J, Iorio MV, Piovan C, Romano G, Croce CM.

Nucleic Acids Res. 2009 Jan;37(Database issue):D41-8. doi: 10.1093/nar/gkn702. Epub 2008 Oct 22.

36.

MicroRNA signatures in human ovarian cancer.

Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, Calin GA, Ménard S, Croce CM.

Cancer Res. 2007 Sep 15;67(18):8699-707.

37.

Relationship between p53 and p27 expression following HER2 signaling.

Casalini P, Iorio MV, Berno V, Bergamaschi A, Børresen Dale AL, Gasparini P, Orlandi R, Casati B, Tagliabue E, Ménard S.

Breast. 2007 Dec;16(6):597-605. Epub 2007 Jun 28.

38.

A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia.

Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM.

N Engl J Med. 2005 Oct 27;353(17):1793-801. Erratum in: N Engl J Med. 2006 Aug 3;355(5):533.

39.

miR-15 and miR-16 induce apoptosis by targeting BCL2.

Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM.

Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9. Epub 2005 Sep 15. Erratum in: Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2464.

40.

MicroRNA gene expression deregulation in human breast cancer.

Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM.

Cancer Res. 2005 Aug 15;65(16):7065-70.

41.

Role of HER receptors family in development and differentiation.

Casalini P, Iorio MV, Galmozzi E, Ménard S.

J Cell Physiol. 2004 Sep;200(3):343-50. Review.

PMID:
15254961
42.

HER2 signaling enhances 5'UTR-mediated translation of c-Myc mRNA.

Galmozzi E, Casalini P, Iorio MV, Casati B, Olgiati C, Ménard S.

J Cell Physiol. 2004 Jul;200(1):82-8.

PMID:
15137060
43.

Mutations in the TMPRSS3 gene are a rare cause of childhood nonsyndromic deafness in Caucasian patients.

Wattenhofer M, Di Iorio MV, Rabionet R, Dougherty L, Pampanos A, Schwede T, Montserrat-Sentis B, Arbones ML, Iliades T, Pasquadibisceglie A, D'Amelio M, Alwan S, Rossier C, Dahl HH, Petersen MB, Estivill X, Gasparini P, Scott HS, Antonarakis SE.

J Mol Med (Berl). 2002 Feb;80(2):124-31. Epub 2001 Dec 18.

PMID:
11907649

Supplemental Content

Loading ...
Support Center